A detailed history of Foresite Capital Management Iii, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Foresite Capital Management Iii, LLC holds 1,111,112 shares of VRNA stock, worth $38 Million. This represents 29.98% of its overall portfolio holdings.

Number of Shares
1,111,112
Previous 1,111,112 -0.0%
Holding current value
$38 Million
Previous $4.66 Million 143.9%
% of portfolio
29.98%
Previous 16.89%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

BUY
$7.08 - $9.33 $7.87 Million - $10.4 Million
1,111,112 New
1,111,112 $9.29 Million
Q4 2020

Feb 16, 2021

SELL
$5.51 - $8.11 $6.12 Million - $9.01 Million
-1,111,112 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$4.45 - $10.2 $4.94 Million - $11.3 Million
1,111,112 New
1,111,112 $6.93 Million
Q1 2019

May 14, 2019

SELL
$5.52 - $10.0 $1.14 Million - $2.07 Million
-206,663 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$9.0 - $13.47 $2.65 Million - $3.96 Million
-294,220 Reduced 58.74%
206,663 $1.99 Million
Q3 2018

Nov 13, 2018

SELL
$11.65 - $14.1 $22,624 - $27,382
-1,942 Reduced 0.39%
500,883 $6.27 Million
Q2 2018

Aug 14, 2018

SELL
$13.66 - $21.0 $853,299 - $1.31 Million
-62,467 Reduced 11.05%
502,825 $6.87 Million
Q1 2018

May 15, 2018

BUY
$11.69 - $20.97 $431,010 - $773,163
36,870 Added 6.98%
565,292 $11.3 Million
Q4 2017

Feb 13, 2018

SELL
$10.8 - $15.75 $868,633 - $1.27 Million
-80,429 Reduced 13.21%
528,422 $6.27 Million
Q3 2017

Nov 13, 2017

SELL
$11.96 - $16.95 $56,810 - $80,512
-4,750 Reduced 0.77%
608,851 $9.35 Million
Q2 2017

Aug 14, 2017

BUY
N/A
613,601
613,601 $7.15 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.08B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Foresite Capital Management Iii, LLC Portfolio

Follow Foresite Capital Management Iii, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.